ADTX - Zillow Group Futu Holdings among premarket losers' pack
Revance Therapeutics (NASDAQ:RVNC) -33% after FDA declines to approve wrinkle injection. MannKind (NASDAQ:MNKD) -18% as FDA declines to approve United Therapeutics’ heart disease drug Omeros (NASDAQ:OMER) -17% after FDA fails to approve narsoplimab treatment. Aditxt (NASDAQ:ADTX) -16% on pricing $4.25 million public offering. Avadel Pharmaceuticals (NASDAQ:AVDL) -14% after FDA says it needs more time to review narcolepsy candidate. TSR (NASDAQ:TSRI) -10%. Nxt-ID (NASDAQ:NXTD) -10%. LM Funding America (NASDAQ:LMFA) -9%. UP Fintech Holding (NASDAQ:TIGR) -9%. BiomX (NYSE:PHGE) -7% after mid-stage results from BX001 skin acne study. Futu Holdings (NASDAQ:FUTU) -7%. Zillow Group (NASDAQ:ZG) -7% to pause home purchases after building up backlog - Bloomberg. Cemtrex (NASDAQ:CETX) -6%. Latch (NASDAQ:LTCH) -6%. Jasper Therapeutics (NASDAQ:JSPR) -6%. DatChat (NASDAQ:DATS) -6%. Ocugen (NASDAQ:OCGN) -6% announces inducement grants Standard Lithium (NYSE:SLI) -5%.
For further details see:
Zillow Group, Futu Holdings among premarket losers' pack